secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001104659-23-088621
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q2 2023 revenue $1.61B (+4% ex-FX); adj. EPS $1.31; FY guidance narrowed
--------------------------------------------------------------------------------

- GAAP diluted EPS $0.95; non-GAAP adjusted diluted EPS $1.31 vs $1.25 prior year.
- Women's Health revenue $438M (+10% ex-FX); Nexplanon up 12% ex-FX; fertility +17% ex-FX.
- Biosimilars $135M (+15% ex-FX); Renflexis +20% ex-FX; Hadlima launched in US July 1.
- Established Brands $995M (flat ex-FX); expects flat full-year revenue.
- FY 2023 revenue guidance narrowed to $6.25-6.45B; adj. EBITDA margin 31.5%-33.0%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465923088621/0001104659-23-088621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465923088621/tm2322580d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer